Prolgolimab
mAbexperimental
Clinical trial activity
11 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
9
Phase 3
5
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT03050047)
Timeline
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314998 ↗
Also known as
- bcd-100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05757466 | Phase 2 | Apr 19, 2023 | Government of Russia, Pavlov First Saint Petersburg State Medical University |
| NCT05732805 | Phase 3 | Aug 2, 2022 | Biocad |
| NCT06428487 | Phase 2 | Mar 31, 2022 | Blokhin's Russian Cancer Research Center |
| NCT05783882 | Phase 3 | Feb 1, 2022 | Biocad |
| NCT03912415 | Phase 3 | Sep 1, 2019 | Biocad |
| NCT03913923 | Phase 2 | Jul 31, 2019 | Biocad |
| NCT03912389 | Phase 3 | Jun 30, 2019 | Biocad |
| NCT03912402 | Phase 2 | Dec 25, 2018 | Biocad |
| NCT03288870 | Phase 2/Phase 3 (Phase 3) | Oct 15, 2017 | Biocad |
| NCT03269565 | Phase 2 | Aug 31, 2017 | Biocad |
| NCT03050047 | Phase 1 | Sep 1, 2016 | Biocad |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biocad | For profit | 9 | 9 | 3 | 2016 |
| Blokhin's Russian Cancer Research Center | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Government of Russia | Government | 1 | 0 | 1 | 2023 |
| Pavlov First Saint Petersburg State Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1